SCHEMBL4515236

SCHEMBL4515236

C=[C][C]=C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL639752 0.67
SCHEMBL11572300 0.63
SCHEMBL399355 0.63
SCHEMBL4739407 0.63
Ammonia Solution, Strong SCHEMBL6518320 0.60
SCHEMBL144636 0.60
Water SCHEMBL277569 0.60
Ammonia Solution, Strong SCHEMBL11413772 0.60
Hydrogen Sulfide SCHEMBL11679956 0.60
SCHEMBL1056772 0.60

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0230300-B1 COMPOSITIONS WHICH ARE RETICULABLE BY MEANS OF PHOTOPOLYMERISATION BASF Aktiengesellschaft (DE) 1990-11-07 EP claimed
US-4921775-A Elements having layers containing mixtures which can be crosslinked by photopolymerization BASF AKTIENGESELLSCHAFT (DE) 1990-05-01 US claimed
EP-0230300-A2 Compositions which are reticulable by means of photopolymerisation BASF Aktiengesellschaft (DE) 1987-07-29 EP claimed
US-20240180941-A1 ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE FLAGSHIP PIONEERING INNOVATIONS V INC (US) 2024-06-06 US disclosed
EP-4377311-A1 2-DIAZO-3-OXO-2,3-DIHYDROSPIRO[INDENE-1,9'-XANTHENE] DERIVATIVES AND SIMILAR COMPOUNDS AS PHOTOACTIVE FLUORESCENT COMPOUNDS FOR PROTEIN LABELING Eikon Therapeutics Inc. (US) 2024-06-05 EP disclosed
US-11998610-B2 Conjugates and methods of using the same FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2024-06-04 US disclosed
US-11981703-B2 Polynucleotide constructs SIRIUS THERAPEUTICS, INC. (US) 2024-05-14 US disclosed
US-11813272-B2 Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2023-11-14 US disclosed
US-20230321083-A1 Inhibitors of GPR174 and Uses Thereof OMEROS CORP (US) 2023-10-12 US disclosed
US-20230285556-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER OMEROS CORPORATION 2023-09-14 US disclosed
US-20230242567-A1 CHIRAL PHOSPHORAMIDITE AUXILIARIES AND METHODS OF THEIR USE SIRIUS THERAPEUTICS, INC. 2023-08-03 US disclosed
US-20170114341-A1 POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS BRADSHAW CURT W (US) 2017-04-27 US disclosed
EP-3152308-A2 POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS Solstice Biologics, Ltd. (IE) 2017-04-12 EP disclosed
US-20160257961-A1 POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS BRADSHAW CURT W (US) 2016-09-08 US disclosed
WO-2016094677-A2 MONONUCLEOTIDES HAVING A BIOREVERSIBLE DISULFIDE GROUP SOLSTICE BIOLOGICS, LTD. (IE) 2016-06-16 WO disclosed
WO-2015188197-A2 POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS SOLSTICE BIOLOGICS, LTD. (IE) 2015-12-10 WO disclosed
US-20090056802-A1 Practical method and means for mechanosynthesis and assembly of precise nanostructures and materials including diamond, programmable systems for performing same; devices and systems produced thereby, and applications thereof RABANI ELI MICHAEL 2009-03-05 US disclosed
EP-0230300-B1 COMPOSITIONS WHICH ARE RETICULABLE BY MEANS OF PHOTOPOLYMERISATION BASF Aktiengesellschaft (DE) 1990-11-07 EP disclosed
US-4921775-A Elements having layers containing mixtures which can be crosslinked by photopolymerization BASF AKTIENGESELLSCHAFT (DE) 1990-05-01 US disclosed
EP-0230300-A2 Compositions which are reticulable by means of photopolymerisation BASF Aktiengesellschaft (DE) 1987-07-29 EP disclosed